CVS Health Unit to Pay $315 Million to Resolve Illegal Opioid Prescription Claims
By Katherine Hamilton
CVS Pharmacy, a unit of CVS Health, agreed to pay $315 million to resolve allegations that it illegally filled opioid prescriptions and submitted false claims for Medicare to pay for them.
The U.S. government alleged that CVS knowingly filled prescriptions for controlled substances that lacked a legitimate medical purpose, weren't valid or weren't issued in the usual course of professional practice.
It also claimed that CVS dispensed prescriptions for dangerous and excessive quantities of opioids, or filled prescriptions too early.
Many of these prescriptions were ultimately billed to or reimbursed by federal healthcare programs, the Justice Department claimed.
In addition to the payment, CVS entered a memorandum of agreement with the Drug Enforcement Agency to address future obligations in dispensing controlled substances.
The agreement requires CVS to establish a hotline for employees and the public to report suspected illegal dispensing of controlled substances.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
October 13, 2026 14:23 ET (18:23 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
United States